What is the BiotechSign catalyst score for ARWR?

ARWR currently has a BiotechSign catalyst score of 56/100 and grade C. Scores combine FDA, clinical trial, insider, dilution, sentiment, short interest, and convergence signals.

What signals does BiotechSign track for ARWR?

BiotechSign tracks 0 active signals for ARWR, including 0 PDUFA signals, 0 insider buying signals, and 0 clinical trial signals when available.

When was the ARWR catalyst page updated?

This ARWR page was refreshed from BiotechSign data on 2026-07-19.

You have used your free lookups for today

Upgrade to BiotechSign Pro for unlimited company access, full signal history, watchlist alerts, and 125+ PDUFA dates.

Upgrade to Pro →← Back to screener

← Back to Screener

ARWR — Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals

RNAi TherapeuticsScore: 56/100Full Profile

What is the current ARWR catalyst setup?

ARWR is tracked by BiotechSign with a current catalyst score of 56/100 and grade C. The page summarizes 0 active signals, including 0 PDUFA, 0 insider buying, and 0 clinical trial signals, with data refreshed on 2026-07-19.

Company SnapshotUpdated 2026-07-19

As of 2026-07-19, Arrowhead Pharmaceuticals (ARWR) has a BiotechSign Catalyst Score of 56/100, rated C. The company has 0 active signals tracked by BiotechSign. BiotechSign scores combine FDA pipeline data, clinical trial activity, SEC insider filings, dilution risk, and sentiment analysis into a single catalyst grade.

This data is for informational purposes only and does not constitute financial or medical advice. Biotech and pharmaceutical stocks carry extreme risk, including binary FDA outcomes that can result in total loss. Always conduct your own due diligence. Source: BiotechSigns (biotechsign.com).

Analyst Summary

Verified 2026-04-11

Arrowhead Pharmaceuticals (ARWR) is the lead sponsor of 16 active clinical trials listed on ClinicalTrials.gov^[4], including 7 Phase 3^[1], 7 Phase 2^[2], 8 Phase 1^[3].

Trial NCT06822790^[5] evaluates Plozasiran Injection in Hypertriglyceridemia with a target enrollment of 869 participants. Trial NCT05089084^[6] evaluates Plozasiran in Familial Chylomicronemia with a target enrollment of 75 participants. Trial NCT07037771^[7] evaluates zodasiran Injection in Homozygous Familial Hypercholesterolemia with a target enrollment of 60 participants.

No Form 4 insider filings for ARWR were recorded at the SEC in the past 30 days^[8].

Sources

ClinicalTrials.gov (2026-04-11) ↗
ClinicalTrials.gov (2026-04-11) ↗
ClinicalTrials.gov (2026-04-11) ↗
ClinicalTrials.gov (2026-04-11) ↗
ClinicalTrials.gov · NCT06822790 (2026-03-23) ↗
ClinicalTrials.gov · NCT05089084 (2026-02-04) ↗
ClinicalTrials.gov · NCT07037771 (2026-03-27) ↗
SEC EDGAR · 0000879407 (2026-04-11) ↗

Not financial advice. BiotechSign scores are for informational purposes only and do not constitute investment recommendations. Always do your own due diligence before making investment decisions.